Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to conduct a Breathing Rate and Pulse Rate accuracy validation comparing the NuraLogix AMC-SDK to the Reference devices, an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex-Ohmeda) and a standard ECG (GE Datex-Ohmeda) derived heart rate reference. This will be done by manually scoring the collected waveform for data analysis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06298981
Study type Observational
Source Nuralogix Corporation
Contact Roberto Liddi
Phone (647) 578-7925
Email robertoliddi@nuralogix.ai
Status Recruiting
Phase
Start date February 12, 2024
Completion date June 30, 2024